Westfield Capital Management Co. LP Sells 27,858 Shares of Ascendis Pharma A/S $ASND

Westfield Capital Management Co. LP trimmed its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,451,401 shares of the biotechnology company’s stock after selling 27,858 shares during the period. Ascendis Pharma A/S makes up 3.9% of Westfield Capital Management Co. LP’s portfolio, making the stock its 2nd biggest position. Westfield Capital Management Co. LP owned 8.91% of Ascendis Pharma A/S worth $940,912,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. RA Capital Management L.P. boosted its position in Ascendis Pharma A/S by 1.7% in the 1st quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock valued at $1,602,474,000 after buying an additional 168,752 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Ascendis Pharma A/S by 12.0% in the first quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company’s stock worth $475,970,000 after acquiring an additional 328,278 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Ascendis Pharma A/S by 1.3% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,901,843 shares of the biotechnology company’s stock worth $328,258,000 after acquiring an additional 23,926 shares in the last quarter. Invesco Ltd. boosted its holdings in Ascendis Pharma A/S by 3.7% in the first quarter. Invesco Ltd. now owns 1,198,478 shares of the biotechnology company’s stock valued at $186,795,000 after purchasing an additional 42,465 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Ascendis Pharma A/S by 10.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 585,581 shares of the biotechnology company’s stock valued at $91,269,000 after purchasing an additional 55,164 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Wells Fargo & Company restated an “overweight” rating and set a $295.00 price objective (up from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Bank of America lifted their price target on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Royal Bank Of Canada increased their price objective on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Stifel Nicolaus raised their price objective on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a “buy” rating in a report on Friday, August 8th. Finally, UBS Group restated a “buy” rating and issued a $307.00 target price (up previously from $306.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $256.60.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $212.15 on Thursday. Ascendis Pharma A/S has a one year low of $118.03 and a one year high of $223.18. The company has a 50-day simple moving average of $202.65 and a 200-day simple moving average of $185.66. The firm has a market capitalization of $13.09 billion, a PE ratio of -41.11 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $290.24 million for the quarter, compared to analysts’ expectations of $246.91 million. Equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.